Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Tekla Life Sciences Investors (HQL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: HQL (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 47.5% | Avg. Invested days 47 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 368.99M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.68 | 52 Weeks Range 10.55 - 15.90 | Updated Date 06/29/2025 |
52 Weeks Range 10.55 - 15.90 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 14.79% | Basic EPS (TTM) -0.48 |
Earnings Date
Report Date 2025-06-09 | When After Market | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -100.99% |
Management Effectiveness
Return on Assets (TTM) -0.32% | Return on Equity (TTM) 1.28% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 368989472 | Price to Sales(TTM) 112.61 |
Enterprise Value 368989472 | Price to Sales(TTM) 112.61 | ||
Enterprise Value to Revenue 10.64 | Enterprise Value to EBITDA - | Shares Outstanding 28872400 | Shares Floating - |
Shares Outstanding 28872400 | Shares Floating - | ||
Percent Insiders 0.01 | Percent Institutions 30.72 |
Upturn AI SWOT
Tekla Life Sciences Investors
Company Overview
History and Background
Tekla Life Sciences Investors (HQL) is a closed-end fund focused on investing in companies involved in the life sciences industry. The fund was established to provide investors with exposure to the growth potential of the healthcare and biotechnology sectors.
Core Business Areas
- Investment Management: HQL invests primarily in public and private companies in the life sciences industry. The fund focuses on areas such as pharmaceuticals, biotechnology, medical devices, diagnostics, and healthcare services. The goal is to deliver current income and long-term capital appreciation.
Leadership and Structure
HQL is managed by Tekla Capital Management LLC. Key personnel includes the portfolio managers who oversee investment decisions and the research team that analyzes investment opportunities.
Top Products and Market Share
Key Offerings
- Closed-End Fund Investments: HQL's primary product is its closed-end fund structure, allowing investors to buy and sell shares on the stock exchange. The fund invests in a diverse portfolio of life sciences companies. No specific market share for this investment fund itself. Competitors: BlackRock Health Sciences Trust (BME), Columbia Seligman Premium Technology Growth Fund (STK).
Market Dynamics
Industry Overview
The life sciences industry is characterized by innovation, regulatory scrutiny, and significant growth potential. Factors like an aging population, advances in medical technology, and increased healthcare spending drive the industry. Investing in biotechnology and healthcare are seen to outperform during a recession. The industry is also influenced by regulatory changes and clinical trial outcomes.
Positioning
HQL aims to capture the growth of the life sciences industry by investing in a mix of established and emerging companies. HQL differentiates itself with a focused approach on specific sub-sectors and utilizes an experienced management team.
Total Addressable Market (TAM)
The global healthcare market is estimated to be in the trillions of dollars. HQL is positioned to capitalize on the growth within life sciences through its investment approach.
Upturn SWOT Analysis
Strengths
- Experienced Management Team
- Focused Investment Strategy
- Diversified Portfolio
Weaknesses
- Market Volatility
- Regulatory Risks
- Dependence on Research & Development
Opportunities
- Emerging Technologies
- Aging Population
- Increasing Healthcare Spending
Threats
- Economic Downturn
- Increased Competition
- Patent Expirations
Competitors and Market Share
Key Competitors
- BME
- STK
Competitive Landscape
HQL competes with other healthcare and biotechnology-focused closed-end funds. Its performance depends on its investment strategy and management team's ability to identify and capitalize on opportunities.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is dependent on the life sciences market performance and manager's choices. The total return is impacted by market fluctuations.
Future Projections: Future growth projections for HQL depend on the outlook for the life sciences industry and the fund manager's investment acumen. Access analyst estimates on financial websites.
Recent Initiatives: Recent initiatives involve adjustments to the portfolio allocation, and active fund management.
Summary
Tekla Life Sciences Investors (HQL) offers exposure to the growth potential of the life sciences industry through a closed-end fund structure. HQL's strengths lie in the management team and investment strategy, but it faces risks from market volatility and regulations. The future growth depends on capitalizing on new technologies and healthcare trends. Investors should consider their risk tolerance and investment goals.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Financial websites
- Company reports
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Tekla Life Sciences Investors
Exchange NYSE | Headquaters Philadelphia, PA, United States | ||
IPO Launch date 1992-05-04 | CEO - | ||
Sector Financial Services | Industry Asset Management | Full time employees - | |
Full time employees - | |||
Abrdn Life Sciences Investors is a closed-ended equity mutual fund launched and managed by abrdn Inc. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. Abrdn Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.